150 related articles for article (PubMed ID: 35316833)
1. Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method.
Vachon CM; Murray J; Allmer C; Larson D; Norman AD; Sinnwell JP; Dispenzieri A; Kleinstern G; Visram A; Kyle RA; Rajkumar SV; Slager SL; Kumar SK; Murray DL
Blood Adv; 2022 Jun; 6(12):3746-3750. PubMed ID: 35316833
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
El-Khoury H; Lee DJ; Alberge JB; Redd R; Cea-Curry CJ; Perry J; Barr H; Murphy C; Sakrikar D; Barnidge D; Bustoros M; Leblebjian H; Cowan A; Davis MI; Amstutz J; Boehner CJ; Lightbody ED; Sklavenitis-Pistofidis R; Perkins MC; Harding S; Mo CC; Kapoor P; Mikhael J; Borrello IM; Fonseca R; Weiss ST; Karlson E; Trippa L; Rebbeck TR; Getz G; Marinac CR; Ghobrial IM
Lancet Haematol; 2022 May; 9(5):e340-e349. PubMed ID: 35344689
[TBL] [Abstract][Full Text] [Related]
3. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement.
Murray D; Kumar SK; Kyle RA; Dispenzieri A; Dasari S; Larson DR; Vachon C; Cerhan JR; Rajkumar SV
Blood Cancer J; 2019 Dec; 9(12):102. PubMed ID: 31836698
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance.
Vachon CM; Kyle RA; Therneau TM; Foreman BJ; Larson DR; Colby CL; Phelps TK; Dispenzieri A; Kumar SK; Katzmann JA; Rajkumar SV
Blood; 2009 Jul; 114(4):785-90. PubMed ID: 19179466
[TBL] [Abstract][Full Text] [Related]
5. Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma.
Greenberg AJ; Rajkumar SV; Larson DR; Dispenzieri A; Therneau TM; Colby CL; Phelps TK; Kumar SK; Katzmann JA; Kyle RA; Slager SL; Vachon CM
Br J Haematol; 2012 May; 157(4):472-5. PubMed ID: 22629552
[TBL] [Abstract][Full Text] [Related]
6. [Monoclonal gammopathy of undetermined significance--potential risk factor of multiple myeloma].
Stelmach-Gołdyś A; Czarkowska-Paczek B
Przegl Lek; 2012; 69(5):194-6. PubMed ID: 23050415
[TBL] [Abstract][Full Text] [Related]
7. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
8. Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster.
Landgren O; Zeig-Owens R; Giricz O; Goldfarb D; Murata K; Thoren K; Ramanathan L; Hultcrantz M; Dogan A; Nwankwo G; Steidl U; Pradhan K; Hall CB; Cohen HW; Jaber N; Schwartz T; Crowley L; Crane M; Irby S; Webber MP; Verma A; Prezant DJ
JAMA Oncol; 2018 Jun; 4(6):821-827. PubMed ID: 29710195
[TBL] [Abstract][Full Text] [Related]
9. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.
Landgren O; Gridley G; Turesson I; Caporaso NE; Goldin LR; Baris D; Fears TR; Hoover RN; Linet MS
Blood; 2006 Feb; 107(3):904-6. PubMed ID: 16210333
[TBL] [Abstract][Full Text] [Related]
10. Characterizing M-protein light chain glycosylation via mass spectrometry.
Miller ID; Kohlhagen MC; Ladwig PM; Dasari S; Kumar S; Dispenzieri A; Willrich MAV; Murray DL
Clin Biochem; 2022; 109-110():11-16. PubMed ID: 36113628
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of monoclonal gammopathy of undetermined significance in Asia: a viewpoint from nagasaki atomic bomb survivors.
Iwanaga M; Tomonaga M
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):18-20. PubMed ID: 24461807
[TBL] [Abstract][Full Text] [Related]
12. [Monoclonal gammopathy of undetermined significance and evolution to myeloma: Experience in 153 patients].
López Gómez JM; Sacristán Enciso B; Fernández-Cavada Pollo MJ; Bueno García V; Gómez Vera S
Semergen; 2021 Oct; 47(7):441-447. PubMed ID: 34479794
[TBL] [Abstract][Full Text] [Related]
13. Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics.
Clay-Gilmour AI; Kumar S; Rajkumar SV; Rishi A; Kyle RA; Katzmann JA; Murray DL; Norman AD; Greenberg AJ; Larson DR; O'Byrne MM; Slager SL; Vachon CM
Leukemia; 2019 Feb; 33(2):499-507. PubMed ID: 30201985
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Monoclonal Gammopathy of Undetermined Significance in Black South African Men.
Cicero KI; Joffe M; Patel M; Chiuzan C; Pentz A; Ruff P; Lentzsch S; Leng S; Jacobson JS; Rebbeck TR; Neugut AI
Cancer Epidemiol Biomarkers Prev; 2022 Dec; 31(12):2192-2198. PubMed ID: 36126958
[TBL] [Abstract][Full Text] [Related]
15. Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance: An Operation Ranch Hand Veteran Cohort Study.
Landgren O; Shim YK; Michalek J; Costello R; Burton D; Ketchum N; Calvo KR; Caporaso N; Raveche E; Middleton D; Marti G; Vogt RF
JAMA Oncol; 2015 Nov; 1(8):1061-8. PubMed ID: 26335650
[TBL] [Abstract][Full Text] [Related]
16. Detection of serum M-protein in acetonitrile precipitates by MALDI-TOF mass spectrometry: A novel, low-cost methodology.
Mehra N; Gopisetty G; Subramani J; Dhanasekar S; Rajamanickam A; Perumal Kalaiyarasi J; Karunakaran P; Kannan K; Rajaraman S; Rajkumar T
Ann Clin Biochem; 2023 Sep; 60(5):339-348. PubMed ID: 37158306
[TBL] [Abstract][Full Text] [Related]
17. [Monoclonal gammopathy of uncertain significance (MGUS) and ionizing radiation].
Taino G; Buonocore C; Stanga A; Imbriani M
G Ital Med Lav Ergon; 2020 Dec; 42(4):292-297. PubMed ID: 33600657
[TBL] [Abstract][Full Text] [Related]
18. Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population.
Lee DJ; El-Khoury H; Tramontano AC; Alberge JB; Perry J; Davis MI; Horowitz E; Redd R; Sakrikar D; Barnidge D; Perkins MC; Harding S; Mucci L; Rebbeck TR; Ghobrial IM; Marinac CR
Blood Adv; 2024 Apr; 8(7):1737-1746. PubMed ID: 38212245
[TBL] [Abstract][Full Text] [Related]
19. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics.
Greenberg AJ; Rajkumar SV; Vachon CM
Blood; 2012 Jun; 119(23):5359-66. PubMed ID: 22354002
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
